Add like
Add dislike
Add to saved papers

Over-Expression of miR-21 and Lower PTEN Levels in Wilms' Tumor with Aggressive Behavior.

Wilms' tumor (WT) is the most common pediatric kidney tumor. MiR-21 is one of the most frequently overexpressed microRNAs in solid tumors, while phosphatase and tensin homolog deleted from chromosome 10 (PTEN) is the most highly mutated tumor suppressor gene. The aim of this study was to investigate the relationship between miR-21 and PTEN in WT. The expression levels of miR-21 and the PTEN protein were determined by qRT-PCR and Western blot analyses in WT specimens, respectively. In WT tissues, the miR-21 expression levels were significantly higher and the PTEN protein levels were significantly lower, compared to the adjacent non-tumorous renal tissues. The higher levels of miR-21 and lower levels of PTEN were correlated with age (> 24 months), late clinical stage, unfavorable histopathological type and lymphatic metastasis. A univariate linear regression analysis indicated a significant correlation between higher miR-21 levels and lower PTEN levels. Using the SK-NEP-1 WT cell line, we showed that the decreased expression levels of miR-21 promoted cell proliferation and invasion, but inhibited apoptosis. Importantly, lowered expression levels of miR-21 increased the expression levels of PTEN protein and decreased the expression levels of phosphoinositide 3-kinase (PI3K) and phosphorylated protein kinase B (p-AKT), each of which functions in the downstream signaling pathway. Dual luciferase-reporter assays indicated that PTEN mRNA was a direct target of miR-21. In conclusion, higher miR-21 levels and lower PTEN protein levels are predictive biomarkers for poor prognosis of WT patients. Over-expression of miR-21 promotes aggressive behavior of WT by targeting PTEN.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app